Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aicuris today announced positive results from its pivotal Phase 3 trial evaluating pritelivir in immunocompromised patients with refractory HSV
-
NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
-
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Alumis Announces Pricing of Upsized Public Offering of Common Stock
-
Alumis Announces Proposed Public Offering of Common Stock
-
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
-
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
-
December 1, 2025 Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical...
-
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.
-
MoonLake Immunotherapeutics investors that lost money are notified to contact BFA before the December 15, 2025 securities fraud class action deadline.